Irene Braña

12.1k total citations
137 papers, 2.6k citations indexed

About

Irene Braña is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Irene Braña has authored 137 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Oncology, 49 papers in Molecular Biology and 49 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Irene Braña's work include Cancer Immunotherapy and Biomarkers (39 papers), Lung Cancer Treatments and Mutations (27 papers) and Cancer Genomics and Diagnostics (26 papers). Irene Braña is often cited by papers focused on Cancer Immunotherapy and Biomarkers (39 papers), Lung Cancer Treatments and Mutations (27 papers) and Cancer Genomics and Diagnostics (26 papers). Irene Braña collaborates with scholars based in Spain, United States and Canada. Irene Braña's co-authors include Josep Tabernero, Lillian L. Siu, Jordi Rodón, Rodrigo Dienstmann, Emiliano Calvo, Johanna C. Bendell, Geoffrey I. Shapiro, José Baselga, Analía Azaro and Juan Manuel Sepúlveda-Sánchez and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Irene Braña

127 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Irene Braña Spain	26	1.3k	1.3k	601	413	359	137	2.6k
Albiruni R. Abdul Razak Canada	29	2.0k 1.5×	1.1k 0.9×	1.1k 1.9×	639 1.5×	571 1.6×	96	3.5k
Nicholas W. Choong United States	19	1.8k 1.4×	1.7k 1.3×	595 1.0×	260 0.6×	221 0.6×	48	2.8k
Paul Frankel United States	34	1.9k 1.5×	1.8k 1.4×	967 1.6×	388 0.9×	658 1.8×	214	4.1k
Drew Rasco United States	33	2.4k 1.9×	1.7k 1.4×	980 1.6×	870 2.1×	516 1.4×	192	4.1k
Amy E. McKee United States	24	1.3k 1.0×	686 0.5×	605 1.0×	370 0.9×	339 0.9×	37	2.3k
Christina S. Baik United States	27	2.1k 1.6×	1.3k 1.0×	1.8k 3.0×	339 0.8×	685 1.9×	116	3.5k
V.A. Miller United States	22	2.1k 1.6×	924 0.7×	1.6k 2.7×	218 0.5×	508 1.4×	83	3.0k
Marta Guix Spain	17	1.4k 1.1×	1.1k 0.9×	714 1.2×	133 0.3×	599 1.7×	43	2.5k
Francisco Robert United States	28	1.8k 1.4×	1.1k 0.9×	1.4k 2.3×	175 0.4×	312 0.9×	107	3.2k
Wing‐Kai Chan Taiwan	22	1.4k 1.1×	1.4k 1.1×	1.2k 2.0×	204 0.5×	828 2.3×	57	3.2k

Countries citing papers authored by Irene Braña

Since Specialization

Citations

This map shows the geographic impact of Irene Braña's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Irene Braña with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Irene Braña more than expected).

Fields of papers citing papers by Irene Braña

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Irene Braña. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Irene Braña. The network helps show where Irene Braña may publish in the future.

Co-authorship network of co-authors of Irene Braña

This figure shows the co-authorship network connecting the top 25 collaborators of Irene Braña. A scholar is included among the top collaborators of Irene Braña based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Irene Braña. Irene Braña is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tahara, Makoto, Richard Greil, Danny Rischin, et al.. (2025). Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study. European Journal of Cancer. 221. 115395–115395. 6 indexed citations

Cho, Byoung Chul, Irene Braña, Beatriz Cirauqui, et al.. (2024). Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study. BMC Cancer. 23(S1). 1254–1254. 5 indexed citations

Aymerich, Clàudia, Irene Braña, Antonio Rullan, et al.. (2024). A comprehensive examination of mental health in patients with head and neck cancer: systematic review and meta-analysis. JNCI Cancer Spectrum. 8(3). 12 indexed citations

Rullan, Antonio, et al.. (2024). A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies. Cancer Treatment Reviews. 128. 102772–102772. 10 indexed citations

Aymerich, Clàudia, Antonio Rullan, Irene Braña, et al.. (2024). Mapping the mental health correlates of head and neck cancer: A systemic review and meta-analysis.. Journal of Clinical Oncology. 42(16_suppl). 6077–6077.

Toledo, Rodrigo A., Oriol Mirallas, Ana Carolina Ramos Moreno, et al.. (2024). Prognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors in the context of phase 1 clinical trials.. Journal of Clinical Oncology. 42(16_suppl). 2510–2510. 2 indexed citations

Lakhani, Nehal J., Omid Hamid, Irene Braña, et al.. (2024). A phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results.. Journal of Clinical Oncology. 42(16_suppl). 2650–2650. 2 indexed citations

Förster, Martin, Irene Braña, Antonio López–Pousa, et al.. (2024). Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 30(17). 3726–3734. 8 indexed citations

Navarro, Vı́ctor, Marta Ligero, Alonso García-Ruiz, et al.. (2024). Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in Cancer. Radiology Artificial Intelligence. 6(2). e230118–e230118. 15 indexed citations

10.

Greil, Richard, Barbara Burtness, Simon Laban, et al.. (2023). 106P Treatment sequencing in PD-L1–positive recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Exploratory analysis of the phase III KEYNOTE-048 study. Immuno-Oncology Technology. 20. 100578–100578. 1 indexed citations

11.

Ho, Alan L., Douglas R. Adkins, George J. Hanna, et al.. (2023). LBA47 A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study). Annals of Oncology. 34. S1286–S1287. 4 indexed citations

12.

Jové, Maria, Irene Braña, María Victoria Maliandi, et al.. (2023). 937P Survival outcomes in phase I trial combining VCN-01 and durvalumab (MEDI4736) in subjects with recurrent/metastatic head and neck squamous cell carcinoma refractory to previous immunotherapy treatment. Annals of Oncology. 34. S589–S590. 1 indexed citations

13.

Subbiah, Vivek, Irene Braña, Alessandra Longhi, et al.. (2022). Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. Clinical Cancer Research. 28(13). 2762–2770. 18 indexed citations

14.

Olmedo, M.E., Martin Förster, Víctor Moreno, et al.. (2021). Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study. Investigational New Drugs. 39(5). 1275–1283. 14 indexed citations

15.

Bahleda, Rastislav, Fadi S. Braiteh, Ani Sarkis Balmanoukian, et al.. (2017). Long-Term Safety and Clinical Outcomes of Atezolizumab in Head and Neck Cancer: Phase Ia Trial Results. Annals of Oncology. 28. v373–v373. 21 indexed citations

16.

Shapiro, Geoffrey I., Katherine M. Bell‐McGuinn, Julian R. Molina, et al.. (2015). First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clinical Cancer Research. 21(8). 1888–1895. 97 indexed citations

17.

Azaro, Analía, Jordi Rodón, Antonio Calles, et al.. (2015). A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Investigational New Drugs. 33(3). 710–719. 25 indexed citations

18.

Rodón, Jordi, Michael A. Carducci, Juan Manuel Sepúlveda-Sánchez, et al.. (2014). First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. Clinical Cancer Research. 21(3). 553–560. 200 indexed citations

19.

Cosimo, Serena Di, Sriram Sathyanarayanan, Johanna C. Bendell, et al.. (2014). Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial. Clinical Cancer Research. 21(1). 49–59. 48 indexed citations

20.

Shapiro, Geoffrey I., Jordi Rodón, Cynthia Bedell, et al.. (2013). Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 20(1). 233–245. 123 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact